AR and pachyonychia congenita: Currently, the potential role of triplet therapies encompassing androgen deprivation therapy (ADT), chemotherapy, and androgen receptor (AR) target agents (ARTAs), is gaining more attention, especially for metastatic hormone-sensitive PC [25].